Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Sun Pharma Inds
Join Channel
Consolidated Standalone

Sun Pharma Inds.

₹1802.2 -2.6 | 0.1%

Market Cap ₹432408 Cr.

Stock P/E 44.8

P/B 6.3

Current Price ₹1802.2

Book Value ₹ 288.1

Face Value 1

52W High ₹1960.2

Dividend Yield 0.75%

52W Low ₹ 1209

Edit Ratio

Sun Pharma Inds. Research see more...

Overview Inc. Year: 1993Industry: Pharmaceuticals & Drugs

Sun Pharmaceutical Industries Ltd is an multinational pharmaceutical company. The Company is engaged in the business of manufacturing, growing and marketing various generic formulations. It produces a portfolio of generic and speciality medicines concentrated on a spectrum of chronic and acute treatments. The Company's product portfolio consists of generics, branded generics, over-the-counter (OTC)/client healthcare products, speciality, anti-retrovirals (ARVs), active pharmaceutical elements (APIs) and intermediates. Its over the counter brands includes Faringosept , Revital, and Volini. The Company offers its products in types of dosage forms, which includes capsules, pills, sprays, injectables, inhalers, ointments, creams and beverages. Its portfolio of speciality merchandise, branded generics are available in 100 international locations. The Company operates production sites across 6 continents.

Read More..

Sun Pharma Inds. Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Sun Pharma Inds. Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 10762 10952 11241 10931 11941 12192 12381 11983 12653 13291
Other Income 148 85 174 373 206 294 375 606 533 482
Total Income 10910 11038 11415 11304 12147 12486 12755 12589 13185 13773
Total Expenditure 8023 7996 8237 8129 8611 9013 9028 8948 9045 9481
Operating Profit 2887 3042 3178 3175 3536 3473 3727 3641 4140 4293
Interest 14 19 46 93 81 49 35 74 62 69
Depreciation 588 610 660 672 651 633 622 650 655 626
Exceptional Income / Expenses 0 0 0 -171 -323 0 -70 -102 0 0
Profit Before Tax 2285 2412 2471 2240 2481 2791 3000 2816 3424 3598
Provision for Tax 189 152 283 223 468 390 432 149 552 567
Profit After Tax 2096 2260 2188 2017 2013 2401 2568 2667 2871 3031
Adjustments -35 2 -22 -32 10 -25 -44 -12 -36 9
Profit After Adjustments 2061 2262 2166 1984 2023 2376 2524 2655 2836 3040
Adjusted Earnings Per Share 8.6 9.4 9 8.3 8.4 9.9 10.5 11.1 11.8 12.7

Sun Pharma Inds. Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 16080 27392 28109 31308 26416 29066 32838 33498 38654 43886 48497 50308
Other Income 552 566 658 1030 912 1059 652 859 1437 694 1628 1996
Total Income 16633 27958 28767 32338 27328 30125 33489 34357 40092 44579 50125 52302
Total Expenditure 9081 19543 19950 21626 20881 22792 25863 25030 28773 32298 35748 36502
Operating Profit 7552 8414 8817 10712 6447 7333 7626 9327 11319 12281 14377 15801
Interest 44 579 523 400 518 555 303 141 127 172 238 240
Depreciation 409 1195 1038 1265 1500 1753 2053 2080 2144 2529 2557 2553
Exceptional Income / Expenses -2517 -238 -685 0 -951 -1214 -261 -4306 -4567 -171 -494 -172
Profit Before Tax 4581 6403 6571 9048 3479 3810 5010 2799 4481 9408 11088 12838
Provision for Tax 702 915 914 1212 911 601 823 515 1076 848 1439 1700
Profit After Tax 3879 5488 5657 7836 2568 3209 4187 2285 3406 8561 9648 11137
Adjustments -738 -949 -1111 -872 -472 -544 -422 619 -133 -87 -72 -83
Profit After Adjustments 3141 4539 4546 6964 2096 2665 3765 2904 3273 8474 9576 11055
Adjusted Earnings Per Share 15.2 21.9 18.9 29 8.7 11.1 15.7 12.1 13.6 35.3 39.9 46.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 11% 13% 11% 12%
Operating Profit CAGR 17% 16% 14% 7%
PAT CAGR 13% 62% 25% 10%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 45% 33% 33% 8%
ROE Average 16% 13% 11% 14%
ROCE Average 18% 15% 12% 15%

Sun Pharma Inds. Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 18525 25638 32982 36640 38314 41409 45264 46463 48011 55995 63667
Minority's Interest 1921 2851 4085 3791 3884 3314 3860 3017 3055 3320 3439
Borrowings 49 1368 3110 1436 1772 1523 2029 898 230 0 1
Other Non-Current Liabilities 1700 967 -941 -836 -1726 -1446 -1783 -2413 -1546 -1998 -2732
Total Current Liabilities 5990 16147 13144 17887 19864 17340 15706 16146 17208 19906 16984
Total Liabilities 28184 46972 52381 58917 62109 62139 65077 64110 66958 77225 81359
Fixed Assets 6817 12682 15872 17675 18853 21837 22847 21553 22665 24065 23211
Other Non-Current Assets 2680 5373 6568 8289 11620 9233 10576 12115 9428 13276 14673
Total Current Assets 18686 28916 29934 32947 31636 31069 31654 30442 34865 39862 43433
Total Assets 28184 46972 52381 58917 62109 62139 65077 64110 66958 77225 81359

Sun Pharma Inds. Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 2069 4359 7183 8032 8642 7906 7062 5677 6273 4508 4624
Cash Flow from Operating Activities 3959 5616 6686 7082 3907 2196 6555 6170 8985 4959 12135
Cash Flow from Investing Activities -2367 -2866 -4372 -4222 -3371 -681 -2589 536 -5725 -7944 -690
Cash Flow from Financing Activities 507 -1187 -1889 -2285 -1539 -2731 -5715 -5980 -5193 2376 -6710
Net Cash Inflow / Outflow 2099 1563 426 575 -1003 -1215 -1749 726 -1934 -608 4735
Closing Cash & Cash Equivalent 4359 7286 8032 8642 7906 7062 5677 6273 4508 4624 9286

Sun Pharma Inds. Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 15.17 21.92 18.89 29.03 8.73 11.11 15.69 12.1 13.64 35.32 39.91
CEPS(Rs) 20.7 32.27 27.82 37.93 16.95 20.68 26.01 18.19 23.13 46.22 50.87
DPS(Rs) 1.5 3 1 3.5 2 2.75 4 7.5 10 11.5 13.5
Book NAV/Share(Rs) 89.44 123.49 137.03 152.7 159.69 172.59 188.66 193.65 200.11 233.38 265.36
Core EBITDA Margin(%) 43.01 28.37 28.64 30.66 10.81 11.14 11.74 13.78 14.71 26.4 26.29
EBIT Margin(%) 28.42 25.24 24.9 29.92 7.81 7.75 8.94 4.78 6.86 21.83 23.35
Pre Tax Margin(%) 28.15 23.14 23.07 28.65 6.79 6.76 8.43 4.55 6.67 21.44 22.86
PAT Margin (%) 23.83 19.84 19.86 24.82 5.02 5.7 7.05 3.72 5.07 19.51 19.9
Cash Profit Margin (%) 26.35 24.16 23.5 28.82 7.94 8.81 10.5 7.1 8.26 25.27 25.17
ROA(%) 16.21 14.6 11.39 14.08 4.24 5.17 6.58 3.54 5.2 11.88 12.17
ROE(%) 23.15 24.89 19.32 22.51 6.85 8.05 9.66 4.98 7.21 16.46 16.13
ROCE(%) 25.46 25.06 18.64 21.48 8.4 8.68 10.07 5.66 9.28 17.24 17.6
Receivable days 51.72 48.2 76.12 80.78 53.53 54.1 56.22 54.88 53.09 91.17 85.38
Inventory Days 63.92 57.99 77.46 76.61 48.88 47.84 48.4 50.1 48.68 80.83 76.7
Payable days 156.28 125.09 203.18 178.34 227.43 206.74 152.86 158.71 149.21 174.1 194.01
PER(x) 37.8 46.64 43.38 23.69 56.72 43.14 22.44 49.38 67.07 27.84 40.6
Price/Book(x) 6.41 8.28 5.98 4.5 3.1 2.78 1.87 3.09 4.57 4.21 6.11
Dividend Yield(%) 0.26 0.29 0.12 0.51 0.4 0.57 1.14 1.26 1.09 1.17 0.83
EV/Net Sales(x) 7.07 7.66 6.85 5.1 4.52 4.07 2.63 4.2 5.57 5.38 7.86
EV/Core EBITDA(x) 15.06 24.92 21.84 14.91 18.51 16.12 11.32 15.1 19.03 19.24 26.51
Net Sales Growth(%) 42.31 70.34 2.62 11.38 -15.63 10.03 12.98 2.01 15.39 13.53 10.51
EBIT Growth(%) 5.97 50.95 1.6 33.18 -57.7 9.23 21.69 -44.64 56.71 107.88 18.22
PAT Growth(%) 11.6 41.49 3.07 38.53 -67.23 24.98 30.46 -45.43 49.07 151.36 12.7
EPS Growth(%) 5.31 44.5 -13.82 53.67 -69.91 27.19 41.25 -22.87 12.7 158.91 13.01
Debt/Equity(x) 0.14 0.35 0.26 0.27 0.27 0.25 0.18 0.08 0.02 0.11 0.04
Current Ratio(x) 3.12 1.79 2.28 1.84 1.59 1.79 2.02 1.89 2.03 2 2.56
Quick Ratio(x) 2.6 1.44 1.79 1.46 1.25 1.34 1.51 1.33 1.51 1.47 1.98
Interest Cover(x) 104.67 12.06 13.56 23.63 7.72 7.86 17.55 20.79 36.19 55.7 47.5
Total Debt/Mcap(x) 0.02 0.04 0.04 0.06 0.09 0.09 0.1 0.03 0 0.03 0.01

Sun Pharma Inds. Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 54.48 54.48 54.48 54.48 54.48 54.48 54.48 54.48 54.48 54.48
FII 14.95 15.99 16.87 16.89 16.48 16.79 17.07 17.72 17.22 18.02
DII 19.66 19.64 19.14 19.24 19.75 19.67 19.52 18.82 19.28 18.61
Public 10.91 9.89 9.52 9.39 9.29 9.07 8.92 8.97 9.02 8.9
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 24% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 13% over the last 3 years.
  • Debtor days have increased from 174.1 to 194.01days.
  • Stock is trading at 6.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Sun Pharma Inds. News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!